UTHRUnited Therapeutics Corporation

$587.51+36% 1Y

$587.51

$415.3452 weeks$596.76

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in and cheap vs its sector, but at the top of its own P/E range.

2 good, 1 to watch

What the price assumes~+8% a year

Priced for ~8% a year FCF growth. The price demands less than its three-year revenue growth of 14% a year, expectations look modest.

Vs its own P/E rangedearest in 37 quartersderived

Expensive vs its own history: P/E 21.0 vs a 12.5 median over 37 quarters (+68% vs median).

Vs sector (EV/EBIT)15.9×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What UTHR's price assumes

United Therapeutics Corporation trades at 21.0× earnings against 21.0× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.

21.0

Trailing P/E · Drug Manufacturers - Specialty & Generic median 21.0 · 1.00× the median: the market pays up for this one

Price / sales: 7.99
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 4.3%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
Growth the price implies: +7.5%
Growth the price implies · The price pays for +7.5% free cash flow growth a year for a decade; the business has delivered +18% a year over the last three.

Details›

Price / booktoday's price, trailing year to Jun 30, 2026: 3.94
EV / EBITtoday's price, trailing year to Jun 30, 2026: 15.9
EV / salestoday's price, trailing year to Jun 30, 2026: 7.06
Healthcare median P/E503 names: 27.9
Drug Manufacturers - Specialty & Generic median P/E44 names: 21.0
Free cash flow, trailing twelve months: $1.09B
Market capitalisation42.9 million shares, counted Jul 29, 2026: $25.2B
3-year revenue growth: +14%
3-year free cash flow growth: +18%

What the market has paid for these earnings: 37 quarters of its own multiple × $27.94 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$288.14
Its own P/E history, median	$349.25
Its own P/E history, upper quartile	$443.50
52-week range	$415.34 – $596.76
Today	$587.51

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.